CSPC Pharmaceutical Group Reports Q1 2025 Earnings

CSPC Pharmaceutical Group ( (CHJTF) ) has released its Q1 earnings. Here is a breakdown of the information CSPC Pharmaceutical Group presented to its investors.

CSPC Pharmaceutical Group Limited is a Hong Kong-based company engaged in the research, development, manufacture, and sale of pharmaceutical products, bulk products, and functional foods, with a focus on innovation and international expansion.

In its latest earnings report for the first quarter of 2025, CSPC Pharmaceutical Group reported a total revenue of RMB7.015 billion, marking a 21.9% decline from the previous year. The company’s profit attributable to shareholders also saw a decrease of 8.4%, amounting to RMB1.478 billion. Despite these declines, the company has been actively repurchasing shares to enhance earnings per share and maximize shareholder returns.

The company’s finished drugs segment experienced a significant revenue drop of 27.3%, largely due to industry policies affecting drug sales. However, the bulk products segment saw a 14.6% increase in sales, driven by the strong demand and price increase of vitamin C products. The functional food and others segment faced an 8.9% revenue decline, attributed to decreased demand and pricing for caffeine products.

Looking ahead, CSPC Pharmaceutical Group remains focused on product internationalization and out-licensing initiatives, which are expected to drive future growth. The company continues to invest in research and development, with numerous products in clinical trials and several regulatory approvals obtained in China and North America.

CSPC Pharmaceutical Group’s management maintains a strategic outlook, emphasizing innovation and global expansion to navigate the challenges posed by industry policies and market dynamics.